Regarding Qianjiang Yong'an Pharmaceutical Co., Ltd. Assurance Report on the 2025 Revenue Deductions Audit Report No. [blank] [blank] [blank] [blank]
To all shareholders of Qianjiang Yong'an Pharmaceutical Co., Ltd.:
We have audited the financial statements of Qianjiang Yong'an Pharmaceutical Co., Ltd. (hereinafter referred to as "Yong'an Pharmaceutical") for the year ended December 31, 2025, including the consolidated and parent company balance sheets, consolidated and parent company income statements, consolidated and parent company cash flow statements, consolidated and parent company statements of changes in owners' equity, and related financial statement notes. We issued an unqualified audit opinion on April 15, 2026, with report number [blank] [blank] [blank] [blank].
Based on the audit of the aforementioned financial statements, we have accepted the engagement to perform reasonable assurance services on the accompanying Yong'an Pharmaceutical 2025 Revenue Deductions Table (hereinafter referred to as the "Revenue Deductions Table").
I. Management's Responsibility The responsibility of Yong'an Pharmaceutical's management is to prepare the Revenue Deductions Table in accordance with the "Stock Listing Rules of the Shenzhen Stock Exchange" and the "Shenzhen Stock Exchange Listed Company Self-Regulatory Management Guidelines No. 1 — Business Handling" and to ensure that the Revenue Deductions Table is true, accurate, and complete, without any false records, misleading statements, or material omissions.